Skip to main content
. 2020 Jul 16;6(1):e12050. doi: 10.1002/trc2.12050

TABLE 4.

Stem cell therapy in clinical trials for Alzheimer's disease (ClinicalTrials.gov accessed February 27, 2020)

Agent Phase Status(CT.gov ID) Sponsor Subjectcharacteristics Amyloid evidence at entry
Allogeneic human MSCs 1

Recruiting

(NCT04040348)

 University of Miami Mild to moderate AD with MMSE of 20‐26 Amyloid PET
Allogeneic human MSCs 1

Active, not recruiting

(NCT02600130)

 Longeveron Mild to moderate AD with MMSE of 18‐24 Amyloid PET
Autologous adipose‐derived MSCs 1/2

Active, not recruiting

(NCT04228666)

 Hope biosciences Preclinical/MCI Amyloid PET
Human umbilical cord blood‐derived MSCs (NEUROSTEM) 1/2

Recruiting

(NCT02054208)

 Medipost Probable AD with KMMSE of 18‐26 Amyloid PET
1/2

Recruiting, extension study

(NCT03172117)

 Medipost Probable AD with KMMSE of 18‐26 Amyloid PET
Human umbilical cord blood‐derived MSCs 1/2

Ongoing

(NCT02672306)

 South China research center, Sun Yat‐Sen University Probable AD with MMSE of 10‐26 Not required
Allogeneic human MSCs 2

Recruiting

(NCT02833792)

 Stemedica Mild to moderate AD with MMSE of 12‐24 Amyloid PET

Abbreviations: AD, Alzheimer's disease; KMMSE, Korea Mini‐Mental State Examination; MMSE, Mini‐Mental State Examination; MSC, mesenchymal stem cell; PET, positron emission tomography.